Versant Capital Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-5,288
| Closed | -$76.5K | – | 2792 |
|
|
2026
Q1 | $76.5K | Hold |
5,288
| – | – | 0.01% | 997 |
|
|
2025
Q4 | $75.3K | Buy |
5,288
+22
| +0.4% | +$216 | 0.01% | 881 |
|
|
2025
Q3 | $41.5K | Buy |
5,266
+4,387
| +499% | +$31.2K | 0.01% | 1135 |
|
|
2025
Q2 | $5.04K | Buy |
879
+470
| +115% | +$3.03K | ﹤0.01% | 2151 |
|
|
2025
Q1 | $3.34K | Buy |
409
+50
| +14% | +$463 | ﹤0.01% | 2176 |
|
|
2024
Q4 | $3.38K | Buy |
+359
| New | +$3.73K | ﹤0.01% | 1932 |
|
|
2024
Q3 | – | Sell |
-593
| Closed | -$5.88K | – | 2039 |
|
|
2024
Q2 | $5.88K | Buy |
593
+565
| +2,018% | +$5.8K | ﹤0.01% | 1166 |
|
|
2024
Q1 | $330 | Hold |
28
| – | – | ﹤0.01% | 1769 |
|
|
2023
Q4 | $397 | Buy |
+28
| New | +$318 | ﹤0.01% | 1730 |
|
|
2020
Q1 | – | Sell |
-19
| Closed | – | – | 1424 |
|
|
2019
Q4 | $0 | Hold |
19
| – | – | ﹤0.01% | 1426 |
|
|
2019
Q3 | $0 | Hold |
19
| – | – | ﹤0.01% | 1432 |
|
|
2019
Q2 | $0 | Sell |
19
-29
| -60% | -$368 | ﹤0.01% | 1499 |
|
|
2019
Q1 | $0 | Hold |
48
| – | – | ﹤0.01% | 1614 |
|
|
2018
Q4 | $0 | Hold |
48
| – | – | ﹤0.01% | 1525 |
|
|
2018
Q3 | $0 | Hold |
48
| – | – | ﹤0.01% | 1560 |
|
|
2018
Q2 | $0 | Hold |
48
| – | – | ﹤0.01% | 1553 |
|
|
2018
Q1 | $0 | Hold |
48
| – | – | ﹤0.01% | 1538 |
|
|
2017
Q4 | $0 | Hold |
48
| – | – | ﹤0.01% | 1560 |
|
|
2017
Q3 | $0 | Hold |
48
| – | – | ﹤0.01% | 1480 |
|
|
2017
Q2 | $0 | Hold |
48
| – | – | ﹤0.01% | 1469 |
|
|
2017
Q1 | $0 | Buy |
+48
| New | +$303 | ﹤0.01% | 1463 |
|
Other funds holding FOLD
Versant Capital Management's FOLD Position: Q2 2026 in Review
Versant Capital Management sold out of Amicus Therapeutics (FOLD) in Q2 2026, closing a stake of 5,288 shares — an estimated $76.5K sold.
Versant Capital Management first reported a position in FOLD in Q1 2017 and held it in 21 quarters. The position peaked at $76.5K in Q1 2026. 1 fund tracked by Wall St. Rank holds FOLD as of Q2 2026.
- Versant Capital Management reported no remaining Amicus Therapeutics position as of Q2 2026 after selling out during the quarter.
- Versant Capital Management sold 5,288 Amicus Therapeutics shares in Q2 2026, an estimated $76.5K.
- Versant Capital Management first reported a position in Amicus Therapeutics in Q1 2017 and held it in 21 quarters.
- Versant Capital Management's Amicus Therapeutics position peaked at $76.5K in Q1 2026.
- 1 fund tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2026.
Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.